| Host |
Mouse |
| Klon |
HMB45+M2-7C10+M2-9E3+T311 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Melanoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse Ig |
| Lokalisation |
Cytoplasm |
Melanoma Cocktail (HMB45 + MART-1 + Tyrosinase)
|
Diagnostic Biosystems |
HMB45+M2-7C10+M2-9E3+T311 |
1 ml |
Concentrate |
CE/IVD |
MOB428 |
-
|
| Host |
Mouse |
| Klon |
HMB45+M2-7C10+M2-9E3+T311 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Melanoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse Ig |
| Lokalisation |
Cytoplasm |
Melanoma Cocktail (HMB45 + MART-1 + Tyrosinase)
|
Diagnostic Biosystems |
HMB45+M2-7C10+M2-9E3+T311 |
0.1 ml |
Concentrate |
CE/IVD |
MOB428-01 |
-
|
| Host |
Mouse |
| Klon |
HMB45+M2-7C10+M2-9E3+T311 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Melanoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse Ig |
| Lokalisation |
Cytoplasm |
Melanoma Cocktail (HMB45 + MART-1 + Tyrosinase)
|
Diagnostic Biosystems |
HMB45+M2-7C10+M2-9E3+T311 |
0.5 ml |
Concentrate |
CE/IVD |
MOB428-05 |
-
|
| Host |
Mouse |
| Klon |
HMB45+M2-7C10+M2-9E3+T311 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Melanoma |
| Verdünnung |
- |
| Isotyp |
Mouse Ig |
| Lokalisation |
Cytoplasm |
Melanoma Cocktail (HMB45 + MART-1 + Tyrosinase)
|
Diagnostic Biosystems |
HMB45+M2-7C10+M2-9E3+T311 |
6 ml |
Ready-to-use |
CE/IVD |
PDM146 |
-
|
| Host |
Mouse |
| Klon |
HMB-45 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Melanoma. |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Extract of pigmented melanoma metastases from lymph nodes |
| Lokalisation |
Cytoplasm |
Melanosome
|
Zeta Corporation |
HMB-45 |
1.0 ml |
Concentrate |
CE/IVD |
Z2088ML |
-
|
| Host |
Mouse |
| Klon |
HMB-45 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Melanoma. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Extract of pigmented melanoma metastases from lymph nodes |
| Lokalisation |
Cytoplasm |
Melanosome
|
Zeta Corporation |
HMB-45 |
7 ml |
Ready-to-use |
CE/IVD |
Z2088MP |
-
|
| Host |
Mouse |
| Klon |
HMB-45 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Melanoma. |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Extract of pigmented melanoma metastases from lymph nodes |
| Lokalisation |
Cytoplasm |
Melanosome
|
Zeta Corporation |
HMB-45 |
0.5 ml |
Concentrate |
CE/IVD |
Z2088MS |
-
|
| Host |
Mouse |
| Klon |
HMB-45 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Melanoma. |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Extract of pigmented melanoma metastases from lymph nodes |
| Lokalisation |
Cytoplasm |
Melanosome
|
Zeta Corporation |
HMB-45 |
0.1 ml |
Concentrate |
CE/IVD |
Z2088MT |
-
|
| Host |
Mouse |
| Klon |
HBME-1 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Mesothelioma. |
| Verdünnung |
1:25-100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
A suspension of mesothelioma cells of human origin |
| Lokalisation |
Cytoplasm |
Mesothelial Cells
|
Zeta Corporation |
HBME-1 |
1.0 ml |
Concentrate |
CE/IVD |
Z2233ML |
-
|
| Host |
Mouse |
| Klon |
HBME-1 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Mesothelioma. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
A suspension of mesothelioma cells of human origin |
| Lokalisation |
Cytoplasm |
Mesothelial Cells
|
Zeta Corporation |
HBME-1 |
7 ml |
Ready-to-use |
CE/IVD |
Z2233MP |
-
|
| Host |
Mouse |
| Klon |
HBME-1 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Mesothelioma. |
| Verdünnung |
1:25-100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
A suspension of mesothelioma cells of human origin |
| Lokalisation |
Cytoplasm |
Mesothelial Cells
|
Zeta Corporation |
HBME-1 |
0.5 ml |
Concentrate |
CE/IVD |
Z2233MS |
-
|
| Host |
Mouse |
| Klon |
HBME-1 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Mesothelioma. |
| Verdünnung |
1:25-100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
A suspension of mesothelioma cells of human origin |
| Lokalisation |
Cytoplasm |
Mesothelial Cells
|
Zeta Corporation |
HBME-1 |
0.1 ml |
Concentrate |
CE/IVD |
Z2233MT |
-
|
| Host |
Mouse |
| Klon |
MSLN-15C11 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Lung, fallopian tube |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 kappa |
| Lokalisation |
Membran for mesotheliomas, cytoplasm for carcinomas |
Mesothelin
|
Biocare Medical |
MSLN-15C11 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3175A |
-
|
| Host |
Mouse |
| Klon |
MSLN-15C11 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Lung, fallopian tube |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 kappa |
| Lokalisation |
Membran for mesotheliomas, cytoplasm for carcinomas |
Mesothelin
|
Biocare Medical |
MSLN-15C11 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3175B |
-
|
| Host |
Mouse |
| Klon |
MSLN-15C11 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Lung, fallopian tube |
| Verdünnung |
- |
| Isotyp |
IgG1 kappa |
| Lokalisation |
Membran for mesotheliomas, cytoplasm for carcinomas |
Mesothelin
|
Biocare Medical |
MSLN-15C11 |
6 ml |
Ready-to-use |
CE/IVD |
API3175AA |
-
|
| Host |
Rabbit |
| Klon |
YP158 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Mesothelioma |
| Verdünnung |
1:10 - 1:15 |
| Isotyp |
IgG |
| Verdünnung |
Synthetic peptide corresponding to C-terminus of human mesothelin protein |
| Lokalisation |
Cell membrane |
Mesothelin
|
Diagnostic Biosystems |
YP158 |
1 ml |
Concentrate |
CE/IVD |
RMAB107 |
-
|
| Host |
Rabbit |
| Klon |
YP158 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Mesothelioma |
| Verdünnung |
1:10 - 1:15 |
| Isotyp |
IgG |
| Verdünnung |
Synthetic peptide corresponding to C-terminus of human mesothelin protein |
| Lokalisation |
Cell membrane |
Mesothelin
|
Diagnostic Biosystems |
YP158 |
0.1 ml |
Concentrate |
CE/IVD |
RMAB107-01 |
-
|
| Host |
Rabbit |
| Klon |
YP158 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Mesothelioma |
| Verdünnung |
1:10 - 1:15 |
| Isotyp |
IgG |
| Verdünnung |
Synthetic peptide corresponding to C-terminus of human mesothelin protein |
| Lokalisation |
Cell membrane |
Mesothelin
|
Diagnostic Biosystems |
YP158 |
0.5 ml |
Concentrate |
CE/IVD |
RMAB107-05 |
-
|
| Host |
Rabbit |
| Klon |
YP158 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Mesothelioma |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Synthetic peptide corresponding to C-terminus of human mesothelin protein |
| Lokalisation |
Cell membrane |
Mesothelin
|
Diagnostic Biosystems |
YP158 |
6 ml |
Ready-to-use |
CE/IVD |
RMPD107 |
-
|
| Host |
Rabbit |
| Klon |
YP158 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Mesothelioma |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Synthetic peptide corresponding to C-terminus of human mesothelin protein |
| Lokalisation |
Cell membrane |
Mesothelin
|
Diagnostic Biosystems |
YP158 |
25 ml |
Ready-to-use |
CE/IVD |
RMPD107-25 |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM25 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Mesothelioma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human mesothelin (MSLN) protein fragment (around aa 273-407) |
| Lokalisation |
Cytoplasm |
Mesothelin
|
Zeta Corporation |
ZM25 |
1 ml |
Concentrate |
CE/IVD |
Z2353ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM25 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Mesothelioma. |
| Verdünnung |
- |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human mesothelin (MSLN) protein fragment (around aa 273-407) |
| Lokalisation |
Cytoplasm |
Mesothelin
|
Zeta Corporation |
ZM25 |
7 ml |
Ready-to-use |
CE/IVD |
Z2353MP |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM25 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Mesothelioma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human mesothelin (MSLN) protein fragment (around aa 273-407) |
| Lokalisation |
Cytoplasm |
Mesothelin
|
Zeta Corporation |
ZM25 |
0.5 ml |
Concentrate |
CE/IVD |
Z2353MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM25 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Mesothelioma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human mesothelin (MSLN) protein fragment (around aa 273-407) |
| Lokalisation |
Cytoplasm |
Mesothelin
|
Zeta Corporation |
ZM25 |
0.1 ml |
Concentrate |
CE/IVD |
Z2353MT |
-
|
| Host |
Mouse |
| Klon |
HBME-1 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Mesothelioma |
| Verdünnung |
1:15 - 1:25 |
| Isotyp |
Mouse IgM |
| Lokalisation |
Cell Membrane |
Mesothelioma
|
Diagnostic Biosystems |
HBME-1 |
1 ml |
Concentrate |
CE/IVD |
MOB349 |
-
|
| Host |
Mouse |
| Klon |
HBME-1 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Mesothelioma |
| Verdünnung |
1:15 - 1:25 |
| Isotyp |
Mouse IgM |
| Lokalisation |
Cell Membrane |
Mesothelioma
|
Diagnostic Biosystems |
HBME-1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB349-01 |
-
|
| Host |
Mouse |
| Klon |
HBME-1 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Mesothelioma |
| Verdünnung |
1:15 - 1:25 |
| Isotyp |
Mouse IgM |
| Lokalisation |
Cell Membrane |
Mesothelioma
|
Diagnostic Biosystems |
HBME-1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB349-05 |
-
|
| Host |
Mouse |
| Klon |
HBME-1 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Mesothelioma |
| Verdünnung |
- |
| Isotyp |
Mouse IgM |
| Lokalisation |
Cell Membrane |
Mesothelioma
|
Diagnostic Biosystems |
HBME-1 |
6 ml |
Ready-to-use |
CE/IVD |
PDM134 |
-
|
| Host |
Mouse |
| Klon |
ZM314 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma, glioma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /k |
| Verdünnung |
Purified His-tagged MGMT protein |
| Lokalisation |
Nucleus |
MGMT
|
Zeta Corporation |
ZM314 |
1 ml |
Concentrate |
CE/IVD |
Z2618ML |
-
|
| Host |
Mouse |
| Klon |
ZM314 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma, glioma |
| Verdünnung |
- |
| Isotyp |
IgG1 /k |
| Verdünnung |
Purified His-tagged MGMT protein |
| Lokalisation |
Nucleus |
MGMT
|
Zeta Corporation |
ZM314 |
7 ml |
Concentrate |
CE/IVD |
Z2618MP |
-
|
| Host |
Mouse |
| Klon |
ZM314 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma, glioma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /k |
| Verdünnung |
Purified His-tagged MGMT protein |
| Lokalisation |
Nucleus |
MGMT
|
Zeta Corporation |
ZM314 |
0.5 ml |
Concentrate |
CE/IVD |
Z2618MS |
-
|
| Host |
Mouse |
| Klon |
ZM314 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma, glioma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /k |
| Verdünnung |
Purified His-tagged MGMT protein |
| Lokalisation |
Nucleus |
MGMT
|
Zeta Corporation |
ZM314 |
0.1 ml |
Concentrate |
CE/IVD |
Z2618MT |
-
|
| Host |
Mouse |
| Klon |
MT3.1 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm, nucleus |
MGMT (O6-Methylguanine DNA Methyltransferase)
|
Diagnostic Biosystems |
MT3.1 |
1 ml |
Concentrate |
CE/IVD |
MOB423 |
-
|
| Host |
Mouse |
| Klon |
MT3.1 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm, nucleus |
MGMT (O6-Methylguanine DNA Methyltransferase)
|
Diagnostic Biosystems |
MT3.1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB423-01 |
-
|
| Host |
Mouse |
| Klon |
MT3.1 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm, nucleus |
MGMT (O6-Methylguanine DNA Methyltransferase)
|
Diagnostic Biosystems |
MT3.1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB423-05 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Normal brain |
| Verdünnung |
1:600 - 1:800 |
| Isotyp |
not determined |
| Lokalisation |
Cytoplasmic |
Microglia (Iba1)
|
Biocare Medical |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
CP290A |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Normal brain |
| Verdünnung |
1:600 - 1:800 |
| Isotyp |
not determined |
| Lokalisation |
Cytoplasmic |
Microglia (Iba1)
|
Biocare Medical |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
CP290B |
-
|
| Host |
Mouse |
| Klon |
34CA5 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
CC1 |
| Positivkontrolle |
Melanoma |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Nuclear |
Microphthalmia Transcription Factor (MiTF)
|
Biocare Medical |
34CA5 |
6 ml |
Ready-to-use |
CE/IVD |
AVI423G |
-
|
| Host |
Mouse |
| Klon |
D5 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Melanoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
N-terminal fragment of human Mi protein. |
| Lokalisation |
Nucleus |
MiTF (Microphthalmia Transcription Factor)
|
Diagnostic Biosystems |
D5 |
1 ml |
Concentrate |
CE/IVD |
MOB462 |
-
|
| Host |
Mouse |
| Klon |
D5 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Melanoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
N-terminal fragment of human Mi protein. |
| Lokalisation |
Nucleus |
MiTF (Microphthalmia Transcription Factor)
|
Diagnostic Biosystems |
D5 |
0.1 ml |
Concentrate |
CE/IVD |
MOB462-01 |
-
|
| Host |
Mouse |
| Klon |
D5 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Melanoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
N-terminal fragment of human Mi protein. |
| Lokalisation |
Nucleus |
MiTF (Microphthalmia Transcription Factor)
|
Diagnostic Biosystems |
D5 |
0.5 ml |
Concentrate |
CE/IVD |
MOB462-05 |
-
|
| Host |
Mouse |
| Klon |
D5 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Melanoma |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
N-terminal fragment of human Mi protein. |
| Lokalisation |
Nucleus |
MiTF (Microphthalmia Transcription Factor)
|
Diagnostic Biosystems |
D5 |
6 ml |
Ready-to-use |
CE/IVD |
PDM168 |
-
|
| Host |
Mouse |
| Klon |
C5/D5 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Melanoma. |
| Verdünnung |
1:50 - 1:200 |
| Isotyp |
IgG1 /κ / IgG1 /κ |
| Verdünnung |
N-terminal fragment of human Mi protein |
| Lokalisation |
Nucleus |
MiTF (Microphthalmia)
|
Zeta Corporation |
C5/D5 |
1.0 ml |
Concentrate |
CE/IVD |
Z2161ML |
-
|
| Host |
Mouse |
| Klon |
C5/D5 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Melanoma. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ / IgG1 /κ |
| Verdünnung |
N-terminal fragment of human Mi protein |
| Lokalisation |
Nucleus |
MiTF (Microphthalmia)
|
Zeta Corporation |
C5/D5 |
7 ml |
Ready-to-use |
CE/IVD |
Z2161MP |
-
|
| Host |
Mouse |
| Klon |
C5/D5 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Melanoma. |
| Verdünnung |
1:50 - 1:200 |
| Isotyp |
IgG1 /κ / IgG1 /κ |
| Verdünnung |
N-terminal fragment of human Mi protein |
| Lokalisation |
Nucleus |
MiTF (Microphthalmia)
|
Zeta Corporation |
C5/D5 |
0.5 ml |
Concentrate |
CE/IVD |
Z2161MS |
-
|
| Host |
Mouse |
| Klon |
C5/D5 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Melanoma. |
| Verdünnung |
1:50 - 1:200 |
| Isotyp |
IgG1 /κ / IgG1 /κ |
| Verdünnung |
N-terminal fragment of human Mi protein |
| Lokalisation |
Nucleus |
MiTF (Microphthalmia)
|
Zeta Corporation |
C5/D5 |
0.1 ml |
Concentrate |
CE/IVD |
Z2161MT |
-
|
| Host |
Mouse |
| Klon |
G168-728 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
1:25 - 1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Full length recombinant MLH-1 |
| Lokalisation |
Nucleus |
MLH-1
|
Zeta Corporation |
G168-728 |
1.0 ml |
Concentrate |
CE/IVD |
Z2076ML |
-
|
| Host |
Mouse |
| Klon |
G168-728 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Full length recombinant MLH-1 |
| Lokalisation |
Nucleus |
MLH-1
|
Zeta Corporation |
G168-728 |
7 ml |
Ready-to-use |
CE/IVD |
Z2076MP |
-
|
| Host |
Mouse |
| Klon |
G168-728 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
1:25 - 1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Full length recombinant MLH-1 |
| Lokalisation |
Nucleus |
MLH-1
|
Zeta Corporation |
G168-728 |
0.5 ml |
Concentrate |
CE/IVD |
Z2076MS |
-
|
| Host |
Mouse |
| Klon |
G168-728 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
1:25 - 1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Full length recombinant MLH-1 |
| Lokalisation |
Nucleus |
MLH-1
|
Zeta Corporation |
G168-728 |
0.1 ml |
Concentrate |
CE/IVD |
Z2076MT |
-
|